Supplementary Figure S7 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer

Ana M. Aparicio; Rebecca S. Tidwell; Shalini S. Yadav; Jiun‐Sheng Chen; Miao Zhang; Jingjing Liu; Shuai Guo; Patrick G. Pilié; Yao Yu; Xingzhi Song; Haswanth Vundavilli; Sonali Jindal; Keyi Zhu; Paul V. Viscuse; Justin M. Lebenthal; Andrew W. Hahn; Rama Soundararajan; Paul G. Corn; Amado Zurita-Saavedra; Sumit K. Subudhi; Jianhua Zhang; Wenyi Wang; Chad Huff; Patricia Troncoso; James P. Allison; Padmanee Sharma; Christopher J. Logothetis

doi:10.1158/1078-0432.26134264.v1

Abstract

Supplementary Figure S7. Major immune cell types derived from bulk RNA sequencing of baseline metastatic lymph node biopsies from patients allocated to the Satisfactory (S) and Unsatisfactory (US) groups.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Aparicio et al. (2024) studied this question.

synapsesocial.com/papers/68e62195b6db6435875b3783 https://doi.org/10.1158/1078-0432.26134264.v1

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S7 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer

Abstract

Discussion

Cite This Study

Supplementary Figure S7 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer

Abstract

Discussion

Cite This Study

Keep reading

Keep reading